bryan_johnson
Public research and commentary from bryan_johnson (@bryan_johnson). Coverage centers on biotech and pharma developments, notable obesity drug trial results, and occasional commentary on athlete enhancement and events.
Past bets that played out
Notable calls highlighted: strong Phase 3 weight-loss data for Eli Lilly’s retatrutide suggesting material implications for Lilly’s leadership in incretin-based obesity therapeutics and market expectations; and public involvement in the “Enhanced Games” broadcast, an event permitting supervised use of FDA‑approved medications under IRB-monitored protocols.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
What this channel is watching now
Top tickers in recent coverage: NVO (mentioned twice), LLY, VKTX, AMGN, and PFE. Recent conviction scores indicate particular emphasis on LLY and VKTX among these mentions.
Latest videos and market context
Recent activity includes announcements of cohosting/broadcasting the Enhanced Games and short-form commentary posts. No paid sponsors or corporate partnerships are identified in the source posts.
@altryne @enhanced_games So many places. They did a great job being social first and making viewing easy and without ...
The post is generic praise for an unnamed product/service being “social first” and making viewing easy; no specific company, product, catalyst, or financial implication is identified.
I’m cohosting the Enhanced Games this Sunday, first time as a broadcaster. It’s the Olympics with enhancement allowed...
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for re...
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
An immortal legacy will never beat being alive.
The source is a motivational statement (“An immortal legacy will never beat being alive.”) with no market, sector, company, macro, or financial content to translate into an actionable investment thesis.
Proof-backed call history
Recent posts mix event announcements and healthcare analysis. Highlights include enthusiastic coverage of Eli Lilly’s Phase 3 weight‑loss results for retatrutide and commentary on the Enhanced Games broadcasting role. Several posts are non‑investment motivational or product praise without actionable market implications.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
About this channel
bryan_johnson publishes concise social commentary and short-form analysis on biotech and healthcare developments, with a focus on impactful clinical trial results and cultural events intersecting with medical ethics and athlete performance.
@bryan_johnson
Most recognized assets
Unlock the full track record
Follow @bryan_johnson for timely commentary on biotech trial results, obesity therapeutics, and occasional event broadcasts related to enhancement and sports.